Sign in to confirm you’re not a bot
This helps protect our community. Learn more

[Unlisted] Could CTD Holdings have a Treatment for Alzheimers?

RedChip Companies
15.3K subscribers
<__slot-el>
<__slot-el>
13K views 5 years ago
CTD Holdings (OTCQB: CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials. The Company’s Scientific Advisory Board endorsed Alzheimer’s Disease (AD) as the company’s next drug development indication. The Company was authorized by the FDA to use Trappsol® Cyclo™ for a late-onset AD patient under a Compassionate Use Program which began intravenous dosing in May 2018. Learn more at CTDHinfo.com. Please read our disclosures: https://www.redchip.com/legal/disclos... ...more
...more
[Unlisted] Could CTD Holdings have a Treatment for Alzheimers?
8Likes
13,389Views
2019Aug 22
CTD Holdings (OTCQB: CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials. The Company’s Scientific Advisory Board endorsed Alzheimer’s Disease (AD) as the company’s next drug development indication. The Company was authorized by the FDA to use Trappsol® Cyclo™ for a late-onset AD patient under a Compassionate Use Program which began intravenous dosing in May 2018. Learn more at CTDHinfo.com. Please read our disclosures: https://www.redchip.com/legal/disclos...

RedChip Companies

15.3K subscribers